ARID1A mutations in endometriosis-associated ovarian carcinomas

New England Journal of Medicine

Volumn 363, Issue 16, 2010, Pages 1532-1543

  Wiegand, Kimberly C ^a,e   Shah, Sohrab P ^a   Al Agha, Osama M ^a   Zhao, Yongjun ^b   Tse, Kane ^b   Zeng, Thomas ^b   Senz, Janine ^a   McConechy, Melissa K ^a   Anglesio, Michael S ^a   Kalloger, Steve E ^a   Yang, Winnie ^a   Heravi Moussavi, Alireza ^a   Giuliany, Ryan ^a   Chow, Christine ^d   Fee, John ^c   Zayed, Abdalnasser ^a   Prentice, Leah ^a   Melnyk, Nataliya ^a   Turashvili, Gulisa ^c   Delaney, Allen D ^b   Madore, Jason ^g   Yip, Stephen ^a   McPherson, Andrew W ^a   Ha, Gavin ^a   Bell, Lynda ^a   Fereday, Sian ^j   Tam, Angela ^b   Galletta, Laura ^j   Tonin, Patricia N ^h   Provencher, Diane ^g,i   Miller, Dianne ^a,e   Jones, Steven J M ^b   Moore, Richard A ^b   Morin, Gregg B ^b,e,f   Oloumi, Arusha ^c   Boyd, Niki ^a   Aparicio, Samuel A ^c,e   Shih, Ie Ming ^l   Mes Masson, Anne Marie ^g,i   Bowtell, David D ^j,k   Hirst, Martin ^b   Gilks, Blake ^d,e   Marra, Marco A ^b,e,f   Huntsman, David G ^a,d,e   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CANADA'S MICHAEL SMITH GENOME SCIENCES CENTRE   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d Genetic Pathology Evaluation Centre   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f SIMON FRASER UNIVERSITY   (Canada)

^g NOTRE DAME HOSPITAL   (Canada)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AT RICH INTERACTIVE DOMAIN 1A; BAF250A PROTEIN; PROTEIN; PROTEIN SWI; TRANSCRIPTION FACTOR SNF; TRANSCRIPTOME; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL CULTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; NONSENSE MUTATION; OVARY CARCINOMA; PRIORITY JOURNAL; RNA SEQUENCE; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; COMPLICATION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; SEQUENCE ANALYSIS, RNA; TRANSCRIPTION FACTORS;

EID: 77957946398     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1008433     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010 July 7 (Epub ahead of print).
2. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010;29:203-11.
3. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99:653-8. (Pubitemid 351448066)
4. Tavassoli FA, Devilee P, eds. Pathology and genetics of tumours of the breast and female genital organs. Vol. 4. of World Health Organization of classification of tumours. Lyon, France: IARC Press, 2003.
5. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
6. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5(12):e232.
7. Dent J, Hall GD, Wilkinson N, et al. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 2003;88:1578-83.
8. Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2009 December 30 (Epub ahead of print).
9. Suehiro Y, Sakamoto M, Umayahara K, et al. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 2000;59:50-6.
10. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007;105:404-8.
11. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-7.
12. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
13. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003;189:280-94.
14. Viganó P, Somigliana E, Chiodo I, Abbiati A, Vercellini P. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update 2006;12:77-89. (Pubitemid 43013749)
15. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009;28:1653-68.
16. Sif S, Saurin AJ, Imbalzano AN, Kingston RE. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev 2001;15:603-18. (Pubitemid 32205148)
17. Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 1996;10:2117-30. (Pubitemid 26303868)
18. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 2007;46:745-50. (Pubitemid 46912345)
19. Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009;360:2719-29.
20. Goya R, Sun MG, Morin RD, et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 2010;26:730-6.
21. Provencher DM, Lounis H, Champoux L, et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000;36:357-61.
22. Lau DH, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991;51:5181-7.
23. Dagan T, Talmor Y, Graur D. Ratios of radical to conservative amino acid replacement are affected by mutational and compositional factors and may not be indicative of positive Darwinian selection. Mol Biol Evol 2002;19:1022-5. (Pubitemid 34743227)
24. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
25. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-601.
26. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 2007;76:51-74.
27. Kozmik Z, Machon O, Králová J, Kreslová J, Paces J, Vlcek C. Characterization of mammalian orthologues of the Drosophila osa gene: cDNA cloning, expression, chromosomal localization, and direct physical interaction with Brahma chromatin-remodeling complex. Genomics 2001;73:140-8.
28. Mitelman F, Johansson B, Mandahl N, Mertens F. Clinical significance of cytogenetic findings in solid tumors. Cancer Genet Cytogenet 1997;95:1-8.
29. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997;15(Special no.):417-74. (Pubitemid 27224668)
30. Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 2001;186:136-45.
31. Wang X, Nagl NG Jr, Flowers S, Zweitzig D, Dallas PB, Moran E. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer 2004;112:636.
32. Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci U S A 2008;105:6656-61.
33. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60:7052-6.
34. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11:63-70. (Pubitemid 40215839)
35. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221:49-56.